{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:10:16Z","timestamp":1768792216047,"version":"3.49.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.blre.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T17:45:30Z","timestamp":1521222330000},"page":"378-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The possible role of maintenance treatment for primary central nervous system lymphoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Osnat","family":"Bairey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2018.03.003_bb0005","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1517\/14656566.2015.1088828","article-title":"Present and future treatment options for primary CNS lymphoma","volume":"16","author":"Citterio","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2018.03.003_bb0010","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11060-016-2318-3","article-title":"Epidemiology for primary brain tumors: a nationwide population-based study","volume":"131","author":"Darlix","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11060-010-0457-5","article-title":"Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma","volume":"104","author":"Bessell","year":"2011","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nox168.287","article-title":"The elderly left behind \u2013 changes in survival trends of primary central nervous system lymphoma over the past four decades","author":"Mendez","year":"2017","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.blre.2018.03.003_bb0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.blre.2018.03.003_bb0040","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","article-title":"Mutational analysis of primary central nervous system lymphoma","volume":"5","author":"Bruno","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2018.03.003_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0050","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11899-014-0217-2","article-title":"Primary CNS lymphoma","volume":"9","author":"Phillips","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2018.03.003_bb0060","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.03.003_bb0065","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0145-2126(06)80002-0","article-title":"Principles of maintenance therapy","volume":"30","author":"Berinstein","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2018.03.003_bb0070","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","article-title":"Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea","volume":"31","author":"Gerber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ncponc0560","article-title":"The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens","volume":"3","author":"Simon","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0080","first-page":"1103","volume":"11","author":"Friedlaender","year":"2015","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.blre.2018.03.003_bb0085","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.03.003_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fonc.2014.00076","article-title":"Metronomics as maintenance treatment in oncology: time for chemo-switch","volume":"4","author":"Malik","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0095","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2018.03.003_bb0100","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2018.03.003_bb0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2018.03.003_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3324\/haematol.2008.001255","article-title":"Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma","volume":"94","author":"Lejeune","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.03.003_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.12344","article-title":"Chronic lymphocytic leukaemia\u2014the role of the microenvironment pathogenesis and therapy","volume":"162","author":"Ramsay","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0130","series-title":"Metronomic chemotherapy in hematological malignancies","author":"Praditsuktavorn","year":"2014"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.03.003_bb0135","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1179\/102453312X13336169155970","article-title":"Metronomic therapy for refractory\/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen","volume":"17","author":"Coleman","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2018.03.003_bb0140","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.03.003_bb0145","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.blre.2018.03.003_bb0150","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1365-2141.1997.3113127.x","article-title":"Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia","volume":"98","author":"Chessells","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V56.1.1.bloodjournal5611","article-title":"Therapy of acute lymphoblastic leukemia in childhood","volume":"56","author":"Mauer","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0160","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2018.03.003_bb0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2018.03.003_bb0175","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0180","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0185","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0190","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0195","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa trial of the Lysa\/Goelams group","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ejh.12412","article-title":"The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma","volume":"94","author":"Joks","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0205","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1053\/j.seminoncol.2016.11.002","article-title":"Recommend maintenance therapy with lenalidomide in multiple myeloma","volume":"43","author":"Manasanch","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0210","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0215","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","article-title":"A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy","volume":"89","author":"Mead","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.03.003_bb0220","article-title":"Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)","volume":"11","author":"Bergner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2018.03.003_bb0225","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2018.03.003_bb0230","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"fFerreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1758834010365330","article-title":"Chemotherapy in newly diagnosed primary central nervous system lymphoma","volume":"2","author":"Hashemi-Sadraei","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.12938","article-title":"Progress in central nervous system lymphomas","volume":"166","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0245","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","article-title":"Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature","volume":"8","author":"Reni","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0250","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2016-01-650101","article-title":"The role of whole brain radiation in primary CNS lymphoma","volume":"128","author":"Kasenda","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0260","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJM200108093450606","article-title":"Toxic leukoencephalopathy","volume":"345","author":"Filley","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0265","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","article-title":"Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma","volume":"24","author":"Gavrilovic","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/nor186","article-title":"Cognitive functions in primary CNS lymphoma after single or combined modality regimens","volume":"14","author":"Correa","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.blre.2018.03.003_bb0275","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0b013e318297eeba","article-title":"Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma","volume":"81","author":"Doolittle","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.blre.2018.03.003_bb0280","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/WNL.0000000000001395","article-title":"Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma","volume":"84","author":"Korfel","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.blre.2018.03.003_bb0285","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0290","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0295","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3109\/10428194.2011.633250","article-title":"Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single Centre experience","volume":"53","author":"Alimohamed","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2018.03.003_bb0300","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0305","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","article-title":"High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma\u2014a randomized phase III trial (MATRix)","volume":"16","author":"Schorb","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2018.03.003_bb0310","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0315","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0320","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0325","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","article-title":"Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly","volume":"22","author":"Fritsch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0330","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0335","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/annonc\/mdn628","article-title":"High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study","volume":"20","author":"Illerhaus","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0340","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/WCO.0000000000000145","article-title":"Challenges in the treatment of elderly patients with primary central nervous system lymphoma","volume":"27","author":"Roth","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.blre.2018.03.003_bb0345","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","article-title":"Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial","volume":"79","author":"Roth","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.blre.2018.03.003_bb0350","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)\u2014a systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0355","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2176\/nmc.32.818","article-title":"Prognosis of primary malignant lymphoma of the central nervous system\u2014a retrospective study of 32 cases","volume":"32","author":"Fusejima","year":"1992","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.blre.2018.03.003_bb0360","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.46.6.1757","article-title":"Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results","volume":"46","author":"Cher","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.blre.2018.03.003_bb0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11060-008-9736-9","article-title":"Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant","volume":"92","author":"Yang","year":"2009","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0370","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/neuonc\/noq011","article-title":"High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma","volume":"12","author":"Chamberlain","year":"2010","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.blre.2018.03.003_bb0375","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","article-title":"Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide","volume":"63","author":"Enting","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.blre.2018.03.003_bb0380","first-page":"2585","article-title":"Temozolomide and treatment of malignant glioma","volume":"6","author":"Friedman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2018.03.003_bb0385","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.20339","article-title":"Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas","volume":"101","author":"Wong","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.03.003_bb0390","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","article-title":"Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly","volume":"85","author":"Omuro","year":"2007","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0395","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.03.003_bb0400","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0405","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2018.03.003_bb0410","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190903128645","article-title":"Maintenance therapy for central nervous system lymphoma with rituximab","volume":"50","author":"Ney","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2018.03.003_bb0415","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2016.1.128","article-title":"Sequencing of chronic lymphocytic leukemia therapies","volume":"2016","author":"Barrientos","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2018.03.003_bb0420","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/17474086.2017.1271318","article-title":"Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications","volume":"10","author":"Lange","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0425","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11864-017-0445-5","article-title":"Treatment of elderly patients with acute myeloid leukemia","volume":"18","author":"Thomas","year":"2017","journal-title":"Curr Treat Options in Oncol"},{"issue":"2","key":"10.1016\/j.blre.2018.03.003_bb0430","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.blre.2018.03.003_bb0435","doi-asserted-by":"crossref","first-page":"5210459","DOI":"10.1155\/2017\/5210459","article-title":"Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies","volume":"2017","author":"Ye","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.blre.2018.03.003_bb0440","first-page":"1","article-title":"Current status of Bruton's tyrosine kinase inhibitor development and use in B-cell malignancies","author":"Aw","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.blre.2018.03.003_bb0445","first-page":"55","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies","volume":"14","author":"Koehrer","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0450","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PPO.0000000000000170","article-title":"Inhibition of the Bruton tyrosine kinase pathway in B-cell lymphoproliferative disorders","volume":"22","author":"Castillo","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2018.03.003_bb0455","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2018.03.003_bb0460","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40265-017-0695-3","article-title":"Ibrutinib: a review in chronic lymphocytic leukaemia","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2018.03.003_bb0465","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2017.1275561","article-title":"Current treatment options and investigational drugs for Waldenstrom's macroglobulinemia","volume":"26","author":"Gavriatopoulou","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.blre.2018.03.003_bb0470","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40265-015-0380-3","article-title":"Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia","volume":"75","author":"Kim","year":"2015","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.blre.2018.03.003_bb0475","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting BTK with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clml.2015.11.011","article-title":"Ibrutinib as a Bruton kinase inhibitor in the management of chronic lymphocytic leukemia: a new agent with great promise","volume":"16","author":"Foluso","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2018.03.003_bb0485","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0490","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcancer.2016.08.001","article-title":"Genetic drivers of NF-kappaB deregulation in diffuse large B-cell lymphoma","volume":"39","author":"Pasqualucci","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2018.03.003_bb0495","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11523-015-0359-8","article-title":"Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma","volume":"10","author":"Keating","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0505","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/17474086.2015.1071663","article-title":"Idelalisib for relapsed\/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes","volume":"8","author":"Davies","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0510","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K Delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2018.03.003_bb0515","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2040620716655350","article-title":"The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia","volume":"7","author":"Itchaki","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0520","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2016.52.4.2470954","article-title":"Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia","volume":"52","author":"Del Poeta","year":"2016","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.blre.2018.03.003_bb0525","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0530","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0535","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/1568009616666160408145741","article-title":"Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia","volume":"16","author":"Riches","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.blre.2018.03.003_bb0540","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/13543784.2016.1208170","article-title":"Lenalidomide for the treatment of B-cell lymphoma","volume":"25","author":"Garciaz","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.blre.2018.03.003_bb0545","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620716652861","article-title":"A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"7","author":"Arora","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0550","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0555","first-page":"10705","article-title":"Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis","volume":"8","author":"Fang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.blre.2018.03.003_bb0560","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"The Lancet Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0570","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.blre.2018.03.003_bb0575","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hon.2315","article-title":"Durable remission in a patient with leptomeningeal relapse of a MYC\/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy","volume":"35","author":"Salati","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0580","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","article-title":"Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018","volume":"29","author":"Warren","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.03.003_bb0585","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.blre.2018.03.003_bb0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.12351","article-title":"Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma","volume":"162","author":"Anwer","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.03.003_bb0595","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \"proof of concept\" phase II study of the French LOC network","volume":"128","author":"Ghesquieres","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0600","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood.V128.22.4170.4170","article-title":"Preclinical evaluation of ibrutinib for central nervous system lymphoma","volume":"128","author":"Pouzoulet","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0605","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2018.03.003_bb0610","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","article-title":"Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse","volume":"126","author":"Bernard","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.03.003_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2018.03.003_bb0620","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccell.2017.05.004","article-title":"Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis","volume":"31","author":"Grommes","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2018.03.003_bb0625","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","article-title":"Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series","volume":"88","author":"Chamoun","year":"2017","journal-title":"Neurology"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17300942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17300942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T04:46:46Z","timestamp":1720154806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X17300942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0268960X17300942"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.03.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The possible role of maintenance treatment for primary central nervous system lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}